Desrosiers RC (2004) Prospects for an AIDS vaccine. Nat Med 10: 221–223.
[2]
Feinberg MB, Moore JP (2002) AIDS vaccine models: Challenging challenge viruses. Nat Med 8: 207–210.
[3]
Haigwood NL (2004) Predictive value of primate models for AIDS. AIDS Rev 6: 187–198.
[4]
Hu SL (2005) Non-human primate models for AIDS vaccine research. Curr Drug Targets Infect Disord 5: 193–201.
[5]
Johnson RP (2006) HIV pathogenesis and vaccine development. Top HIV Med 14: 8–15.
[6]
Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, et al. (2006) HIV vaccine design: Insights from live attenuated SIV vaccines. Nat Immunol 7: 19–23.
[7]
Letvin NL (2006) Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 6: 930–939.
[8]
Lifson JD, Martin MA (2002) One step forwards, one step back. Nature 415: 272–273.
[9]
Malkevitch NV, Robert-Guroff M (2004) A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev Vaccines 3: S105–S117.
[10]
Robinson HL, Amara RR (2005) T cell vaccines for microbial infections. Nat Med 11: S25–S32.
Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ, et al. (2005) Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79: 15547–15555.
[13]
Wilson NA, Reed J, Napoe GS, Piaskowski S, Szymanski A, et al. (2006) Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 80: 5875–5885.
[14]
Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, et al. (1999) Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 73: 8356–8363.
[15]
Robertson M, Mehrotra D, Fitzgerald D, Duerr A, Casimiro D, et al. (2008) Efficacy results from the Step Study (Merck V520 Protocol 023/HVTN 502)—A phase II test-of-concept trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent vaccine [abstract 88LB]. 15th Conference on Retroviruses and Opportunistic Infections; 3–6 February 2008; Boston, Massachusetts, United States of America. Available: http://www.hvtn.org/science/step_buch.ht？ml. Accessed 10 July 2008.
